Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor by Albo, D et al.
Tumour cell invasion is a complex, multistep process that involves
the controlled degradation of the extracellular matrix by tumour
cell-associated proteases (Mignatti, 1993). Generation of plasmin
on the tumour cell surface is believed to play a crucial role in the
process of invasion. Tumour cell-bound plasmin directly degrades
the tumour-associated stroma, activates precursors of proteases
(i.e. matrix metalloproteinases), and activates latent growth factors
stored in the extracellular matrix (i.e., transforming growth factor-
b1). These growth factors then act in a paracrine fashion, further
promoting tumour cell growth and invasion (Testa and Quigley,
1990; Vassalli, 1991). While pericellular proteolysis is crucial for
tumour cell invasion to occur, excessive proteolysis inhibits inva-
sion, presumably by destroying the matrix scaffold that tumour
cells need in order to adhere and migrate (Krishnamurti, 1992;
Hosokawa et al,, 1993). Thus, a controlled proteolysis, with an
adequate temporal and spatial expression of proteases, has to take
place for the process of tumour cell invasion to occur.
One of the main components of the plasminogen/plasmin
system is the urokinase plasminogen activator receptor (uPAR)
(Vassalli, 1985; Plow, 1986; Blasi, 1990; Roldan, 1990). uPAR, a
member of a family of cysteine-rich cell surface proteins, lacks a
transmembrane domain. It is anchored to the cell surface by a
glycosylphosphatidylinositol (GPI) linkage that is synthesized
concurrently to the postranslational removal of the carboxy-
terminal signal sequence (Ploug et al, 1993). Experimental data
has demonstrated that uPAR plays a critical role in tumour inva-
sion and metastasis (Blasi, 1993a; 1993b). In a series of elegant
experiments, inhibition of uPAR resulted in prevention of metas-
tasis, tumour growth and angiogenesis in different in vitro and in
vivo models (Ossowski et al, 1991; Ossowski, 1992; Kariko et al,
1993; Mohanam et al, 1993; Kook et al, 1994; Mohanam et al,
1994; Yu et al, 1997). Furthermore, it has been shown that high
levels of uPAR in primary tumours correlate with their malignant
potential, therefore serving as a prognostic indicator (Graeff,
1992; Costantini et al, 1996). uPAR binds urokinase plasminogen
activator (uPA) in a saturable, reversible, and specific manner,
with a Kd of 0.1–1 nM and maximal binding of 1 ´ 104–2.2 ´ 105
sites per cell (high affinity and low capacity) (Barnathan, 1990).
uPA is the main cell-associated activator of plasmin and it has
been shown to play a key role in tumour invasion and metastasis
(Testa and Quigley, 1990; Ellis, 1991; Ossowski et al, 1991; Blasi,
1993a; 1993b; Mignatti, 1993). uPA levels in primary tumours
have been shown to function as a prognostic indicator (Foekens,
1992).
While degradation of the extracellular matrix is necessary for
tumour cell invasion, excessive matrix degradation has been
shown to inhibit tumour cell migration and prevent invasion
(Krishnamurti, 1992; Hosokawa et al, 1993; Albo et al, 1994;
1997). PAI-1, the main inhibitor of uPA, has been shown to
localize to the extracellular matrix in several malignancies in
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association with matrix proteins such as vitronectin (Seiffert,
1994; Bianchi, 1995). PAI-1 has been shown to promote breast
tumour cell invasion by preventing excessive matrix degradation
by tumour-associated plasmin-mediated proteolytic activity (Albo
et al, 1997). Considerable evidence indicates that increased levels
of tumour-associated PAI-1 are a strong, independent prognostic
indicator of poor clinical outcome in cancer patients (Costantini
et al, 1996; Grondahl-Hansen et al, 1997).
Several extracellular matrix proteins have been shown to modu-
late tumour growth and invasion in a paracrine fashion (Laiho,
1989; Keski-Oja, 1991; Tuszynski et al, 1997). TSP-1 (encoded by
the THBS-1 gene), a large glycoprotein that localizes to the extra-
cellular matrix in several different tumours, has been shown to
play a critical role in tumour progression and invasion (Tuszynski,
1993). TSP-1 has been shown to promote tumour cell adhesion,
migration, invasion and angiogenesis, crucial steps in the process
of metastasis (Tuszynski et al, 1987a; 1987b; Clezardin et al,
1991; Yabkowitz et al, 1993). Our laboratory has shown that
platelet-produced TSP-1 up-regulates uPA and uPAR, increases
plasmin-mediated proteolytic activity in different tumour cells and
promotes tumour cell invasion. Furthermore, we have recently
shown that neutralization of uPA binding to uPAR at the tumour
cell surface with antibodies against either uPA or uPAR results in
inhibition of platelet TSP-1-mediated tumour cell invasion in vitro
(Albo et al, 1994; 1997; Arnoletti, 1995; Wang et al, 1996a;
1996b).
Our previous findings supporting a role for TSP-1 in tumour
cell invasion were generated using human platelet-produced
TSP-1 (Wang et al, 1995; 1996c; Albo et al, 1997; Albo, 1998). A
potential pitfall of these findings is that TSP-1 is a very large
glycoprotein, and, therefore, although platelet produced-TSP-1 is
likely to play a role in the haematogenous phase of tumour spread,
it is not likely to achieve significant concentrations at the tissue
level. Although no significant changes in the structure of platelet-
produced and tumour-produced TSP-1 have been reported,
tumour-produced TSP-1 could have different properties than
platelet-produced TSP-1 in terms of the regulation of the plas-
minogen/plasmin system and tumour cell invasion. In addition,
tumour cells produce TSP-1 in vivo through a paracrine interac-
tion with activated stromal cells, and, therefore, produce small
amounts of TSP-1 when cultured in vitro. In this study we used
breast tumour cells transfected with full-length THBS-1 cDNA
that overexpress TSP-1.
Additionally, our previously published data supporting a role for
the plasminogen/plasmin system in TSP-1-mediated tumour cell
invasion was primarily based on antibody neutralization studies
(Albo et al, 1997; Albo, 1998). The potential problems associated
with the use of antibodies are related to their specificity and the
fact that most of the uPA is bound to uPAR on the cell surface and,
therefore, either uPA and/or uPAR may be protected from inactiva-
tion by their respective antibodies. Additionally, the antibodies
may induce clustering of the receptors and therefore induce
spurious activation of the receptors and their signalling pathways.
Therefore, we developed three other strategies to study the role of
the plasminogen/plasmin system in TSP-1-mediated tumour cell
invasion in addition to the use of neutralizing antibodies: a)
removal of uPAR from the cell surface by cleaving its GPI anchor
with GPI-specific phospholipase C; b) inhibition of uPAR produc-
tion at the mRNA level by using uPAR antisense technology; c)
inhibition of plasminogen binding with e-aminocaproic acid, a
plasminogen receptor antagonist.
MATERIALS AND METHODS
Materials
All reagents, unless otherwise specified, were purchased from
Sigma Chemical Company (St. Louis, MO, USA). The human
breast adenocarcinoma cell line MDA-MB-435 was purchased
from the American Type Culture Collection (HTB 26, Rockville,
MD, USA). MDA-MB-435 cell line was established from pleural
effusions of a patient with metastatic breast cancer. These cells
form invasive tumours in nude mice consistent with a breast
primary. Tissue culture supplies were purchased from Fisher
Scientific Company (Pittsburgh, PA, USA).
THBS-1 transfection
Transfection of MDA-MB-435 cells with the THBS-1 expression
plasmid or unaltered pCMVBamNeo vector using a calcium phos-
phate-based kit (GIBCO-BRL, Gaithersburg, MD, USA) was
previously described (Weinstat-Saslow et al, 1994).
Cell clones
Three clones were selected for this study: TH5 cells (vector alone,
control); TH26 cells (7.5 ´ higher TSP-1 expression than TH5
cells); TH29 cells (4 ´ higher TSP-1 expression than TH5 cells).
All three clones were previously characterized (Weinstat-Saslow
et al, 1994). TSP-1 production by the different clones used was
assessed by Western blot and TSP-1 ELISA.
Cell culture
TH5, TH26 and TH29 cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal calf
serum, 100 units ml–1 of penicillin, 100 mg ml–1 of streptomycin,
and 750 mg ml–1 G418 (GIBCO-BRL). The cultures were main-
tained on plastic and incubated in 5% CO2–95% air at 37°C in a
humidified incubator. Cell cultures were noted to be pathogen-
free. Tumour cells were harvested from subconfluent cultures
(80–90% confluence) by short exposure to 0.02% ethylenediamine
tetraacetic acid (EDTA) solution and re-suspended in serum-free
DMEM before use.
Antisense uPAR transfection
The uPAR antisense construct (LKAS) was previously described
(Yu et al, 1997). Briefly, it consists of a 296-bp uPAR antisense
cDNA fragment subcloned into a BamHI- and HindIII-digested
LK444 vector under a b-actin promoter. Sequence analysis of the
fragment showed 100% homology with the published uPAR
sequence. After three in vitro passages, TH26 cells (7.5 ´ higher
TSP-1 expression than control TH5 cells) were plated at 3 ´ 105
cells per well of a six-well plate, and when 80% confluent, they
were transiently transfected for 6–8 h with 1.5 mg of LK444
(designated LK444–TH26) or LKAS (designated LKAS-TH26)
using 0, 6, 9, 12, or 20 ml of Lipofectin (Gibco Laboratories,
Rockville, MD, USA) in serum-free DMEM according to manu-
facturer’s protocol. After transfection, the cells were incubated for
24 h in DMEM supplemented with 10% FCS. The cells were then
incubated for 24 h in serum-free media. At the end of the incuba-
tion period, tumour cell media were obtained. The cells were300 D Albo et al
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washed with phosphate buffered saline (PBS) and tumour cell
extracts were harvested by adding cold 1% Triton X-100 in
TBS, pH 8.5. The extracts were centrifuged at 10 000 rpm to
remove cell debris. Quantitation of uPAR and uPA and measure-
ment of uPA and plasmin activity were performed as described
below.
Quantitation of uPAR, uPA, PAI-1, TGF-b1 and TSP-1
TH5, TH26, or TH29 cells were plated in six-well plates and
allowed to attach and grow to 80–90% confluency in FCS-
containing medium. The cells were weaned from the FCS-
containing media to a serum-free media over 24 h. The cells were
then incubated for 48 h at 37°C in DMEM supplemented with
0.1% bovine serum albumin (BSA), 100 units ml–1 of penicillin,
100 mg ml–1 of streptomycin, and 750  mg ml–1 G418 with and
without the addition of 100 mg ml–1 of either polyclonal goat anti-
human TSP-1 neutralizing antibody or control goat IgG. At the
end of the incubation period, tumour cell media and extracts were
obtained as described above. uPAR levels in cell extracts were
measured using the IMUBIND total uPAR enzyme-linked
immunosorbent assay kit (American Diagnostica Inc, Greenwich,
CT, USA). uPA concentration in the cell media and extracts from
the different treatment groups was measured using the IMUBIND
total uPA enzyme-linked immunosorbent assay kit (American
Diagnostica Inc). PAI-1 concentration in the cell media from the
different treatment groups was measured using the IMUBIND
total PAI-1 enzyme-linked immunosorbent assay kit (American
Diagnostica Inc). TSP-1 concentrations were measured by a
competitive TSP-1 immunosorbent assay developed in our labora-
tory and previously described (Tuszynski et al, 1987c). The lower
detection limits of the assays are 0.1–2.0 ng total uPAR/uPA/PAI-
1/TSP-1 per ml of sample. Samples of equal amounts of total
protein (as determined by BCA protein analysis) were evaluated.
Assay procedures were performed according to the vendor’s
instructions. Total uPAR, uPA, PAI-1, and TSP-1 levels were
quantitated by measuring solution absorbencies and comparing the
values with those of a standard curve. Results shown are the
average of three separate determinations. Total and activated
TGF-b1 levels in the conditioned media were measured by the
Quantikine human TGF-b1 ELISA assay (R&D Systems,
Minneapolis, MN, USA) following the manufacturer’s protocol.
Western immunoblotting
Tumour cell extract protein concentration was determined by BCA
protein analysis (Bio-Rad Laboratories, Richmond, CA, USA).
Samples of equal amount (approximately 30 mg of total protein per
lane) were fractionated on 8–25% gradient SDS-PAGE and then
transferred to nitrocellulose membranes (Micron Separations Inc,
Westborough, MA, USA) using the Pharmacia phast-gel electro-
phoresis system. Nonspecific binding was blocked with 5% milk
in PBS containing 0.05% Tween 20 (PBS-T) overnight. The
immunoblots were then incubated with either 5 mg ml–1 of poly-
clonal rabbit anti-human uPAR or 80 mg ml–1 polyclonal goat anti-
human TSP-1 IgG for 1 h at room temperature in PBS-T. After
washing, the immunoblots were incubated with horseradish
peroxidase-conjugated anti-rabbit or anti-goat IgG for 45 min. The
bound antibodies were detected using an enhanced chemilumines-
cence (ECL) system (Amersham, Arlington Heights, IL, USA).
uPA and plasmin activities
uPA and plasmin enzymatic activities were determined spectro-
photometrically using uPA or plasmin-specific chromogenic
substrate assays (Spectrozyme UK, American Diagnostica Inc).
Enzymatic levels were measured directly in microtitre plates at
405 nm.
Tumour cell invasion assay
Tumour cell invasion was investigated in a modified Boyden
chamber assay. This assay was employed since it has been demon-
strated that invasiveness in this assay correlates well with the
metastatic potential of a given cell line in vivo (Albini, 1987;
Wang et al, 1996a; 1996b). Polycarbonate filters, 8 mg pore size
(Millicell, Millipore Corporation, Bedford, MA, USA), were
coated with 100 mg type I collagen (1 mg ml–1 in 60% ethanol) and
dried overnight at 25°C. Blind-well Boyden chambers were filled
with 600 ml of DMEM containing 0.1% BSA in the lower
compartment, and the coated filters were mounted in the chamber.
Approximately 50 000 TH5, TH26, TH29, LK444-TH26, or
LKAS-TH26 tumour cells (tested to be greater than 95% viable)
suspended in 400 ml serum-free medium were placed in the upper
chamber of the apparatus and allowed to settle onto the collagen-
coated membrane. After an incubation period of 6 h at 37°C
(previously established in our laboratory), the cells on the upper
surface of the filter were removed with a cotton swab. The filters
were then fixed in 3% glutaraldehyde solution and stained with
0.5% crystal violet solution. Invasive cells adhering to the under-
surface of the filter were counted using a phase contrast micro-
scope (´ 400). The data were expressed as the summation of the
number of invasive tumour cells in five representative fields. All
experiments were performed in triplicate.
In vitro tumour cell invasion inhibition assays
TH26 tumour cell invasion was also determined with the addition
to the upper chamber of either: a) anti-uPA antibody (10 mg ml–1);
b) anti-uPAR antibody (10 mg ml–1); c) GPI-specific phospholipase
C (PLC, 1 IU ml–1), an enzyme that cleaves the GPI anchor that
attaches uPAR to the tumour cell surfaces or; d) e-aminocaproic
acid (ACA, 0.25 M), a lysine analogue that prevents formation of
plasmin at the cell surface by blocking plasminogen binding
(Hajjar, 1995). The number of invasive cells was counted as
described above for the cell invasion assay. Cleavage of uPAR
from the tumour cells by PLC was confirmed by measuring uPAR
on tumour cell extracts and media by ELISA as previously
described.
Tumour cell adhesion assay
Tumour cell adhesion to different substrates was studied as previ-
ously described (Tuszynski and Murphy, 1990). Briefly, 50 ml of
either a 40 mg ml–1 solution of collagen type I, collagen type IV,
laminin, or bovine serum albumin (BSA, negative control)
dissolved in DMEM, pH 7.3, were placed in 96-well microtitre
wells and dried overnight at 25°C. The wells were washed with
PBS and then treated with 200 ml PBS containing BSA for 1 h to
block non-specific binding and then washed three more times with
PBS. Cells were harvested, washed and suspended in serum-free
DMEM. 20 000 TH5, TH26, or LKAS-TH26 tumour cells wereTumour cell thrombospondin-1 promotes tumour cell invasion 301
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added to each well and incubated in serum-free DMEM for 1 h at
37°C in a CO2 incubator. Additionally, 20 000 TH26 tumour cells
treated with 0.25 M e-aminocaproic acid were also plated and
incubated for 1 h. Non-adherent cells were removed by aspiration
and the wells washed three times with PBS. The total cell-associ-
ated protein was determined by dissolving the attached cells
directly in the microtiter wells with 200 ml of the Pierce BCA
working solution (Pierce Chemical Co, Rockford, IL, USA) and
the absorbance of each well was determined at 562 nm with a
microtitre reader plate.
Statistical analysis
All experiments were done in triplicate and performed at least
twice. Values are expressed as the mean ± standard deviation.
Statistical analysis was performed using Sigmastat software
(Jandel Corporation, San Rafael, CA, USA). Where several groups
were compared to a control group, analysis of variance (ANOVA)
and Student–Newman–Keuls method were utilized. P values less
than 0.05 were considered significant. Dose-dependent response
was evaluated by linear regression analysis.
RESULTS
TSP-1 expression
TH5, TH29, and TH26 cells have been previously characterized
(Weinstat-Saslow et al, 1994). TSP-1 expression by TH5, TH29,
and TH26 cells used in this study was confirmed by Western
immunoblot analysis (Figure 1). When media conditioned by these
cells for 48 h were analysed for TSP-1 by ELISA, we found that
TH26 (4.9 mg ml–1) and TH29 (2.6 mg ml–1) cells showed a
7.5- and 4-fold increase respectively, in TSP-1 expression
compared to control TH5 cells (0.66 mg ml–1).
TGF-b1 expression
Variable levels of total (active + inactive) TGF-b1 were observed
in our different cell lines. Total TGF-b1 expression was
210  ± 12 pg 10–1 tumour cells by TH26 cells, 54 ± 3 pg 10–6
tumour cells by TH29 cells and 84 ± 5 pg 10–6 tumour cells by
TH5 cells. However, active TGF-b1 levels were higher in the low-
TSP-1 producing TH5 cells (75 ± 8 pg 10–6 tumour cells) than in
intermediate TSP-1 producing TH29 cells (48 ± 2 pg 10–6 tumour
cells) or in the high TSP-1-producing TH26 cells (58 ± 5 pg 10–6
tumour cells).
The effect of tumour cell-produced TSP-1 on uPAR
expression
TH26 cells and TH29 cells expressed higher uPAR concentrations
in a manner that was directly proportional to the amount of TSP-1
produced by these cells, as demonstrated by ELISA and Western
immunoblotting (Figures 2 and 3). TH5 cells (control), expressed
6.74  ± 0.12 ng ml–1 of uPAR. TH26 cells expressed 34.80 ±
0.12 ng ml–1 of uPAR (5-fold increase). TH29 cells expressed
12.75 ± 0.19 ng ml–1 of uPAR (2-fold increase). The differences
in uPAR expression between the TH26 or TH29 cells and the
TH5 cells were statistically significant (P < 0.01). Addition of
neutralizing anti-TSP-1 antibody to the high TSP-1-producing
TH26 cells significantly decreased uPAR expression by these cells
(9.99  ± 0.37 ng ml–1, P < 0.01 vs TH26 cells alone). Control
IgG showed no effect on TH26 cell uPAR expression (40.3 ±
1.83 ng ml–1).
The effect of tumour cell-produced TSP-1 on uPA
expression
While total uPA production (tumour cell extract + tumour cell
media) was not significantly changed in the TH5, TH26, and
TH29 cells (data not shown), uPA expression on the tumour cell
extracts was 7-fold higher in the TH26 cells and 4-fold higher in
the TH29 cells compared to the control TH5 cells (Figure 2). TH5
cells (control), expressed 0.30 ± 0.12 ng ml–1 of uPA. TH26 cells
expressed 2.14 ± 0.18 ng ml–1 of uPA. TH29 cells expressed 1.20 ±
0.33 ng ml–1 of uPA. The differences in uPA expression between
the TH26 or TH29 cells and the TH5 cells were statistically signif-
icant (P < 0.04). Addition of neutralizing anti-TSP-1 antibody to
the high TSP-1-producing TH26 cells significantly decreased uPA
expression by these cells (0.40 ± 0.10 ng ml–1, P < 0.01 vs TH26
cells alone). Control IgG showed no effect on TH26 cell uPAR
expression (1.98 ± 0.08 ng ml–1).
180 Kd
TH26 TH29 TSP-1
(Control)
TH5
Figure 1 Thrombospondin-1 expression in transfected cell lines. TH5
(transfected with the vector alone), TH26 (THBS-1-transfected; high TSP-1
producer), or TH29 (THBS-1-transfected; low TSP-1 producer) breast cancer
cells were grown to 80–90% confluency in serum-containing media and then
weaned to serum-free media over a 24 h period. After a 24-h incubation in
serum-free media, tumour cell media from the different cell types were
obtained. Samples of equal amount were fractionated on 8–25% gradient
SDS-PAGE and then transferred to a nitrocellulose membrane. Nonspecific
binding was blocked with 5% milk in PBS-T overnight. The immunoblot was
then incubated with 80 mg ml–1 polyclonal goat anti-human TSP-1 IgG for 1 h
at room temperature in PBS-T. After washing, the immunoblots were
incubated with horseradish peroxidase-conjugated anti-goat IgG for 45 min.
The bound antibodies were detected using an enhanced chemiluminescence
system. The 180 Kd band represents non-cleaved TSP-1.
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Figure 2 uPAR and uPA expression in transfected cell lines. TH5, TH26,
TH29, or LKAS-TH26 cells were grown to 80–90% confluency on
FCS-containing medium. The cells were weaned off the FCS-containing
media to a serum-free media over 24 h. After a 48-h incubation period,
tumour cell extracts were obtained by addition of cold 1% Triton X-100. uPAR
and uPA expression were measured by ELISA.302 D Albo et al
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The effect of tumour cell-produced TSP-1 on PAI-1
expression
PAI-1 expression was significantly up-regulated by tumour cell
TSP-1 (Figure 4). While TH5 cells expressed only 0.04 ± 0.02 ng
ml–1 of PAI-1 in their cell media, TH29 cells expressed 1.32 ± 0.20
ng ml–1 and TH26 cells expressed 1.69 ± 0.60 ng ml–1. The differ-
ence in PAI-1 expression between TH5 cells and TH29 or TH26
cells was statistically significant (P < 0.03). The difference in PAI-
1 expression between TH26 and TH29 cells was not statistically
significant (P = 0.25).
The effect of tumour cell-produced TSP-1 on uPA and
plasmin activities
Tumour cell-associated uPA and plasmin activities were higher in
the TSP-1-producing tumour cells in a manner that was directly
proportional to the amount of TSP-1 produced (Figure 5). uPA and
plasmin activity were 50–65% higher in the high TSP-1-producing
tumour cells (TH26 cells) than in the control cells (TH5 cells). The
differences in uPA or plasmin activity between the TH26 and the
TH5 cells were statistically significant (P < 0.01).
The effect of LKAS transfection on TH26 uPAR
expression
Transient uPAR antisense transfection reduced uPAR expression
on TH26 cells by 50–70% (Figures 2 and 3). Reduction of uPAR
expression in the tumour cell extracts was proportional to the dose
of lipofectin used as demonstrated by linear regression analysis (R
= 0.874). Maximum inhibition of uPAR expression was achieved
with 6 ml of lipofectin per 1.5 mg of DNA. Concentrations greater
than 12 ml of lipofectin per 1.5 mg of DNA compromised cell
viability without significantly reducing uPAR expression on the
tumour cells (data not shown). LK444-TH26 (vector control trans-
fected cells) cell extracts expressed similar amounts of uPAR than
the non-transfected tumour cells (33.90 ± 2.69 vs 35.50 ± 1.70 ng
ml–1 of uPAR, respectively, P = 0.67).
The effect of LKAS transfection on TH26 uPA
expression
Although no change in total uPA production (cell extract + media)
was observed, uPA expression was reduced by 50–70% in the
LKAS-TH26 cell extracts (Figure 2). Reduction of uPA expression
in the tumour cell extracts was proportional to the dose of lipo-
fectin used as demonstrated by linear regression analysis (R =
0.870). Maximum inhibition of uPA expression was achieved with
6 ml of lipofectin per 1.5 mg of DNA. Concentrations greater than
12 ml of lipofection per 1.5 mg of DNA compromised cell viability
without significantly reducing uPA expression on the tumour cells
(data not shown). LK444-TH26 (vector control transfected cells)
cell extracts expressed similar amounts of uPA than the non-trans-
fected tumour cells (2.18 ± 0.10 vs 2.32 ± 0.05 ng ml–1 of uPA,
respectively, P = 0.33).
The effect of LKAS transfection on TH26 uPA and
plasmin activities
Antisense uPAR transfection reduced uPA and plasmin activities
on TH26 tumour cells (Figure 5). uPA activity was reduced by
70% on LKAS-TH26 tumour cells compared to control (LK444-
TH26 cells). Plasmin activity was reduced by 73% on LKAS-
TH26 tumour cells compared to control (LK444-TH26 cells). The
differences in uPA or plasmin activity between the LKAS-
TH26 and the LK444–TH5 cells were statistically significant
(P < 0.001).
TH5 TH29 LKAS-
TH26
uPAR
(Control)
TH26
35 Kd
Figure 3 uPAR expression in transfected cell lines. Tumour cell extracts
were obtained as outlined in Figure 2. Additionally, TH26 cells were
transiently co-transfected with the LKAS uPAR antisense construct (cells
named LKAS-TH26) for 6–8 h. After a 36-h incubation in serum-containing
media, tumour cells were placed in serum-free media for 24 h. At that time,
tumour cell extracts were obtained by addition of cold 1% Triton X-100. uPAR
expression in tumour cell extracts was determined by Western immunoblot
analysis by using a polyclonal rabbit anti-human uPAR primary antibody and
the corresponding peroxidase-conjugated anti-rabbit IgG secondary antibody.
The bound antibodies were detected using an enhanced chemiluminescence
system.
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Figure 4 PAI-1 levels in transfected cells. TH5, TH26, or TH29 cells were
grown to 80–90% confluency on FCS-containing medium. The cells were
weaned off the FCS-containing media to a serum-free media over 24 h. After
a 48-h incubation period, tumour cell conditioned media was harvested.
PAI-1 levels were measured by ELISA.
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Figure 5 uPA and plasmin activities in transfected cell lines. Tumour cell
extracts were obtained as outlined in Figure 3. uPA and plasmin activities
were measured by using uPA or plasmin-specific chromogenic substrate
assays. Antisense uPAR transfection (LKAS-TH26 cells) resulted in a 70%
inhibition of plasmin and uPA activities on TH26 cells. Vector control
transfection (LK444–TH26) showed no reduction in activity compared to
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The effect of tumour cell-produced TSP-1 in tumour cell
invasion
Tumour cell invasion correlated with the amount of TSP-1
produced by the different cell lines (Figure 6). TH5 cells showed
8.0 ± 1.0 invasive cells per five high-power fields. TH26 cells
showed 263.5 ± 46.5 invasive cells per five high-power fields
(47.5-fold increase). TH29 cells showed 84.0 ± 21.4 invasive cells
per five high-power fields (10.5-fold increase). The differences in
tumour cell invasion between the TH26 or TH29 cells and the TH5
cells were statistically significant (P < 0.05). Addition of neutral-
izing antibody against TSP-1 significantly decreased the invasive
capacity of TH26 cells (39 ± 2 invasive cells per five high-power
fields, P < 0.01 vs TH26 cells alone). Control IgG did not signifi-
cantly reduce the invasive capacity of TH26 cells (251 ± 27.5
invasive cells per five high-power fields, P = 0.12 vs TH26 cells
alone).
The role of the plasminogen/plasmin system in tumour
cell TSP-1-mediated tumour cell invasion
To determine the role of the plasminogen/plasmin system on
tumour cell TSP-1-mediated tumour cell invasion, different antag-
onists were used (Figure 7). TH26 tumour cell invasion (380.0 ±
27.0 invasive cells per five high-power fields) was inhibited by
blocking uPAR or uPA with neutralizing antibodies (13.5 ± 0.5 and
17.5 ± 8.5 invasive cells per five high-power fields, respectively),
cleaving uPAR from the cell surface with GPI-specific phospho-
lipase C (4.5 ± 0.5 invasive cells per five high-power fields), or
blocking plasminogen binding to the cell surface with the lysine
analogue e-aminocaproic acid (7.5 ± 3.5 invasive cells per five
high-power fields). Furthermore, a comparable inhibition on TH26
tumour cell invasion was achieved by transiently transfecting the
TH26 cells with LKAS (uPAR antisense construct) (16.5 ± 0.5
invasive cells per five high-power fields). The differences in
tumour cell invasion between TH26 cells alone and TH26 cells
plus the addition of a-uPAR, a-uPA, GPI-PLC, e-ACA, or LKAS
were statistically significant (P < 0.005). Transfection of TH26
cells with LK444 (vector control) had no statistically significant
effect on TH26 tumour cell invasion (286.0 ± 16.0 invasive cells
per five high-power fields, P = 0.10).
ELISA confirmed that treatment with GPI-PLC stripped the
TH26 tumour cells of uPAR. uPAR expression on non-treated
TH26 tumour cell extracts and media was 35.99 ± 1.18 ng ml–1 and
0.20  ± 0.50 ng ml–1, respectively. uPAR expression on GPI-
PLC-treated TH26 tumour cell extracts and media was 0.27 ±
0.07 ng ml–1 and 3.5 ng ml–1, respectively.
The effect of tumour cell-produced TSP-1 in tumour cell
adhesion
Tumour cell adhesion was inhibited by tumour cell-produced TSP-
1 (Figure 8). A 2-fold decrease in TH26 tumour cell adhesion to
laminin, type I collagen, and type IV collagen was observed
compared to the TH5 tumour cells. The differences in tumour cell
adhesion to the different substrates between the TH26 and the TH5
cells were statistically significant (P < 0.01). Antisense uPAR
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Figure 6 Tumour cell invasion by transfected cell lines. 50 000 tumour cells
were plated per well of a modified Boyden chamber collagen invasion assay.
After a 6-h incubation period the number of cells traversing the membrane
were counted and expressed as number of invasive cells per five high-power
fields.
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Figure 7 The role of uPAR on TSP-1-mediated tumour cell invasion. 50 000
tumour cells were plated per well of a modified Boyden chamber collagen
invasion assay. Additionally, TH26 cells were incubated in the presense of
anti-TSP-antibody. After a 6-h incubation period the number of cells
traversing the membrane were counted and expressed as number of invasive
cells per five high-power fields. (1) TH26 tumour cells alone. (2) TH26 +
neutralizing anti-uPAR antibody. (3) TH26 + neutralizing anti-uPA antibody;
(4) e-aminocaproic acid-treated TH26 cells. (5) TH26 + GPI-phospholipase C.
(6) LKAS-TH26 (uPAR antisense co-transfected TH26 cells) tumour cells
alone.
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Figure 8 The role of uPAR on tumour cell adhesion. Approximately 20 000
TH5, TH26 (with and without treatment with e-aminocaproic acid) or
LKAS-MDA tumour cells were plated per well of a 96-well microtitre plate
pre-coated with either laminin, type I, or type IV collagen. After a 1-h
incubation period the wells were washed with PBS. Total cell-associated
protein was determined by dissolving the attached cells directly in the
microtitre wells with 200 ml of the Pierce BCA working solution (Pierce
Chemical Co) and the absorbance of each well was determined at 562 nm
with a microtitre reader plate. LKAS-TH26: antisense uPAR transfected
TH26 cells. ACA: e-aminocaproic acid.transfection restored the adhesive capacity of the TH26 cells,
showing that up-regulation of uPAR plays a central role in the
decreased cell adhesion observed in the high TSP-1 producing
cells (Figure 8). In order to determine whether this effect was
related to some intrinsic anti-adhesive effects of the uPAR mole-
cule or related to an enhanced generation of plasmin at the cell
surface, TH26 cells were treated with e-aminocaproic acid.
Blocking binding of plasminogen to the TH26 tumour cell surface
with e-aminocaproic acid also restored the adhesive capacity of
the TH26 tumour cells to control levels (Figure 8). These data
show that the TSP-1-mediated decrease in tumour cell adhesion
involves not only up-regulation of uPAR expression but also the
conversion of plasminogen to plasmin at the tumour cell surface.
DISCUSSION
Pericellular proteolysis plays a crucial role in tumour cell invasion.
The controlled degradation of the extracellular matrix by tumour-
associated proteases allows tumour cells to invade and metastasize
(Mignatti, 1993). Plasmin is believed to play a central role not
only as a proteolytic enzyme capable of cleaving most of the extra-
cellular matrix components but also by activating inactive precur-
sors of other key proteases (i.e. matrix metalloproteinases)
produced by tumour cells and/or tumour-associated stromal cells.
Additionally, during matrix degradation, plasmin can activate
latent growth factors (i.e. TGF-b1) stored in the matrix that have
potent effects on tumour growth and can provide for an amplifica-
tion loop by up-regulating plasmin generation as well (Testa and
Quigley, 1990; Vassalli, 1991).
We have previously established that platelet-produced TSP-1
promotes tumour cell invasion through up-regulation of the key
regulatory components of the plasminogen/plasmin system, uPAR,
uPA, and PAI-1 (Albo et al, 1997). Degradation of the extracellular
matrix in the pericellular environment, such as the one promoted
by uPAR-bound uPA, allows tumour cells to detach from the main
colony and to invade surrounding tissues. By preventing excessive
plasmin-mediated degradation of the extracellular matrix, PAI-1
has been shown to play a crucial role in tumour cell invasion and
metastasis (Bianchi, 1995; Costantinin et al, 1996; Albo et al,
1997; Grondahl-Hansen et al, 1997). Furthermore, although a
study in bladder cancer suggested that TSP-1 levels in the extra-
cellular matrix inversely correlated to tumour growth (Grossfeld
et al, 1997), several studies in breast, head and neck cancers have
demonstrated a direct correlation between high TSP-1 and/or TSP-
1 receptor expression and metastatic potential of the tumours
(Wong et al, 1992; Clezardin et al, 1993; Arnoletti et al, 1994;
Tuszynski and Nicosia, 1994; Roth et al, 1997). The TSP-1-medi-
ated up-regulation of the plasminogen/plasmin system may in part
be responsible for the higher metastatic potential in patients with
higher TSP-1 levels. Additionally, higher blood levels of TSP-1
have been shown in patients with several malignancies, with
patients with higher circulating levels of TSP-1 showing poorer
outcomes (Tuszynski et al, 1992; Nathan et al, 1994; Yamashita et
al, 1998).
Due to its large molecular weight, it is unlikely that the TSP-1
produced in the vascular compartment achieves significant tissue
concentration. Although platelet-produced TSP-1 may indeed play
a key role in the haematogenous spread of tumour cells, it is not
likely to play a role in tissue invasion. Tumours produce TSP-1 in
vivo through a tightly controlled paracrine interaction between
tumour cells and stromal cells (i.e. tumour-associated fibroblasts).
This paracrine interaction produces a very precise pattern of TSP-
1 expression in vivo, with TSP-1 being stored in the matrix, and its
CSVTCG-specific receptor expressed by the tumour cells
(Clezardin et al, 1993; Tuszynski and Nicosia, 1994).
Consequently, tumour cells produce very little amounts of TSP-1
in vitro, making it difficult to study the effect of tumour
cell-produced TSP-1 in tumour cell biology.
In order to overcome this problem, we used THBS-1-transfected
breast cancer cells that overexpress TSP-1. We found that, similar
to the effect of platelet-produced TSP-1, tumour cell-produced
TSP-1 also up-regulates uPAR and uPA expression, uPA and
plasmin activities, and promotes tumour cell invasion proportion-
ally to the amount of TSP-1 produced by the tumour cells. The
uPA receptor seems to play a key role in this TSP-1-mediated
up-regulation in tumour-associated plasmin activity since down-
regulation of uPAR with antisense construct in our experiments
significantly reduced both uPA and plasmin activities in the TH26
tumour cells. Although tumour cell TSP-1 also up-regulated
PAI-1, the overall tumour cell-associated proteolytic activity was
significantly up-regulated by tumour cell TSP-1. Moreover, the
up-regulation of the plasminogen/plasmin system by tumour cell-
produced TSP-1 was significantly higher than the one achieved
when we treated tumour cells with platelet-produced TSP-1 at
concentrations that mimicked those seen in tumour patients
(Arnoletti, 1995; Albo et al, 1997). This could explain the apparent
discrepancy between the increase in tumour cell invasion seen in
this study and the smaller tumours and lower number of lung
metastasis previously reported by Weinstat-Saslow et al in mice
injected with the high TSP-1-producing TH26 cells compared to
those injected with low TSP-1-producing TH5 cells (Weinstat-
Saslow et al, 1994). The excessive amount of TSP-1 expressed by
the TH26 cells may promote excessive tumour cell-associated
proteolysis. It has been well established that while pericellular
proteolysis is fundamental for tumour cell invasion, excessive
proteolysis is detrimental for tumour cell invasion in vivo, since it
decreases tumour cell proliferation and excessively destroys the
matrix scaffold surrounding tumour cells, inhibiting cell adhesion
and migration (Krishnamurti, 1992; Hosokawa et al, 1993). In our
laboratory, we have previously established that at doses that more
closely mimic those seen in cancer patients, platelet-produced
TSP-1, through its CSVTCG-specific receptor, promotes tumour
cell invasion in vitro and metastasis in a murine model (Wang 
et al, 1995; 1996b; 1996c; Albo et al, 1997; Albo, 1998).
Alternatively, TSP-1-transfected tumour cells may produce anti-
angiogenic factors in vivo which would affect tumour growth.
This could explain the lower tumour vascularization and growth
seen in mice injected with TH26 cells as reported by Weinstat-
Saslow.
Previously, it has been reported that TSP-1 can activate TGF-b1
(Schultz-Cherry and Murphy-Ullrich, 1993; Schultz-Cherry et al,
1994a; 1994b). TGF-b1 has been shown to up-regulate the plas-
minogen/plasmin system in other models (Blasi, 1993a; 1993b).
Therefore, in the present study we measured the levels of active
TGF-b1 in the conditioned media of the different cell lines. The
data showed that active TGF-b1 levels were actually higher in our
low TSP-1 producing TH5 cells than in the high TSP-1-producing
TH26 cells. This data suggest that the up-regulation seen in the
plasminogen/plasmin system in response to tumour TSP-1 seen in
our study is not mediated by TGF-b1.
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In previous experiments, we established that neutralization of
uPAR or uPA with antibodies reduced the ability of different
tumour cells to invade in response to platelet-produced TSP-1
(Albo et al, 1997). Although these data were convincing, potential
pitfalls associated with antibody specificity, availability, and the
possibility of cross-linking and spurious activation of receptors
and signaling pathways existed. For these reasons, in addition to
the antibody experiments, we employed two additional strategies.
First, we reduced uPAR expression on the cell surface by enzymat-
ically removing it with GPI-specific phospholipase C. Second and
more specifically, we blocked uPAR expression at the mRNA
level by antisense inhibition. Additionally, in order to determine
whether generation of plasmin at the tumour cell surface was
necessary, we inhibited tumour cell surface plasminogen binding
with the lysine analogue e-aminocaproic acid.
The data showed that neutralization of uPAR (with antibody) or
enzymatic cleavage of uPAR (with GPI-specific phospholipase C)
similarly blocked TSP-1 mediated tumour cell invasion. Although
there is the theoretical possibility that other GPI-anchored surface
proteins could have been responsible for this effect, the antisense
data confirmed the role of uPAR in TSP-1-mediated tumour cell
invasion. Although no change in total uPA production was
observed in the antisense uPAR-transfected cells, a reduction on
cell-associated uPA antigen, uPA activity and plasmin activity that
paralleled the reduction in uPAR expression was observed. These
data strongly suggested that the main role of uPAR in TSP-1 medi-
ated tumour cell invasion was to promote plasmin generation at
the tumour cell surface. Furthermore, e-aminocaproic acid inhib-
ited TSP-1-mediated tumour cell invasion demonstrating that the
generation of plasmin at the tumour cell surface is necessary for
the TSP-1-mediated and uPAR-controlled tumour cell invasion to
occur. The co-localization of enzyme and substrate at the cell
surface favored by TSP-1 allows for an efficient and localized
generation of plasmin at the tumour cell surface. Thus, pericellular
proteolysis and, therefore, tumour cell invasion are promoted in
response to TSP-1.
Tumour cell adhesion plays a crucial role in tumour cell inva-
sion. For tumour cells to metastasize, they must be able to detach
from the primary tumour and migrate. Plasmin-mediated degrada-
tion of the extracellular matrix is thought to be a prerequisite for
tumour cell migration. Although loose attachments to the extracel-
lular matrix are necessary for tumour cells to migrate, it is believed
that the overall adhesive capacity of tumour cells is decreased at
invasive foci (Mignatti, 1993). uPAR-bound uPA has been shown
to be located at tumour cell-substratum focal contact sites, as well
as in areas of tumour cell-cell contact (Pollanen, 1987), co-local-
izing with the intracellular protein vinculin, a specific marker of
such contact sites (Hebert, 1988; Pollanen, 1988). uPAR-bound
uPA has also been shown to play a crucial role in cell migration
(Busso et al, 1994). Our data show that up-regulation of uPAR by
tumour cell-produced TSP-1 decreases the overall adhesive
capacity of the tumour cells to the main components of the extra-
cellular matrix (Type I collagen) and basement membranes (Type
IV collagen and laminin). Furthermore, our data also show that
this uPAR-mediated decrease in tumour cell adhesion depends on
plasmin generation at the tumour cell surface.
Our collective data suggest a crucial role for TSP-1 in the
process of tumour cell invasion, both at the tissue and haematoge-
nous phases. Blocking the plasminogen/plasmin system at
different levels could provide for different, simultaneous and,
perhaps, synergistic approaches for reducing tumour cell invasion.
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